Status:
ACTIVE_NOT_RECRUITING
MTB cfDNA Levels in TBP
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Tuberculosis, Pleural
Eligibility:
All Genders
18+ years
Brief Summary
Tuberculous pleuritis (TBP) is the most common manifestation of extrapulmonary TB. Its diagnosis is challenging due to the low sensitivity of mycobacterial culture from the pleural fluid and the need ...
Detailed Description
Tuberculosis (TB) is one of the major global health threats, with an estimated global incidence of 9.87 million cases in 2020 and it is the second leading infectious cause of death after COVID-19. Apa...
Eligibility Criteria
Inclusion
- Patients hospitalized for unilateral pleural effusion.
- Pleural tapping will be performed for pleural fluid analysis.
- Aged 18 years old or above
Exclusion
- History of tuberculous pleuritis (TBP) and bacterial pleural infection, in either ipsilateral or contralateral pleural space.
- History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.
- History of surgical decortication or pleurodesis in the ipsilateral pleural space
- Use of anti-TB medications (including isoniazid, rifampicin, pyrazinamide, ethambutol, amikacin, streptomycin, levofloxacin, moxifloxacin, linezolid) for more than consecutive 14 days in the past 3 months.
- Failed to obtain informed consent due to patient's refusal or cognitive impairment
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
329 Patients enrolled
Trial Details
Trial ID
NCT05397730
Start Date
September 1 2022
End Date
December 31 2025
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong